PFIZER INC
13F Reported Value
ⓘ$238.8M
Holdings
18
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
PFIZER INC disclosed 18 positions worth $238.8M in its Form 13F-HR for Q1 2026, led by $ORIC (Oric Pharmaceuticals, Inc.) at 24.1% of the equity portfolio, followed by $ALLO and $ARVN. During the quarter the fund opened 1 new position and exited 1 — including a new stake in $AGMB and a full exit from $ANTX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from PFIZER INC’s Form 13F-HR filing with the SEC under CIK 78003.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$57.7M4,780,401 sh - —
Quality
$49.8M22,032,040 sh - 13.9#2,765
Quality
$34.9M3,457,815 sh - —
Quality
$31.3M295,652 sh - —
Quality
$16.8M2,838,913 sh - —
Quality
$11.9M1,875,000 sh - —
Quality
$9.2M7,032,770 sh - 6.1
Quality
$8.3M4,690,431 sh - 19.5
Quality
$5.5M2,362,348 sh - —
Quality
$4.2M505,645 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Oric Pharmaceuticals, Inc.$ORIC | — | $57.7M | 4,780,401 |
 Allogene Therapeutics, Inc.$ALLO | — | $49.8M | 22,032,040 |
 ARVINAS, INC.$ARVN | 13.9#2,765 | $34.9M | 3,457,815 |
 Celcuity Inc.$CELC | — | $31.3M | 295,652 |
 Zura Bio Ltd$ZURA | — | $16.8M | 2,838,913 |
 Wave Life Sciences Ltd.$WVE | — | $11.9M | 1,875,000 |
 Pyxis Oncology, Inc.$PYXS | — | $9.2M | 7,032,770 |
 Caribou Biosciences, Inc.$CRBU | 6.1 | $8.3M | 4,690,431 |
 Spero Therapeutics, Inc.$SPRO | 19.5 | $5.5M | 2,362,348 |
 Biohaven Ltd.$BHVN | — | $4.2M | 505,645 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of PFIZER INC's 18 positions.
Showing top 10 of 18 holdings.
Sector Allocation
Healthcare
$238.8M
Technology
$14,242
Full Holdings — PFIZER INC (Q1 2026)
All 18 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ORIC | Oric Pharmaceuticals, Inc. | $57.7M | 24.1% | -11% | — |
| 2 | $ALLO | Allogene Therapeutics, Inc. | $49.8M | 20.9% | +0% | — |
| 3 | $ARVN | ARVINAS, INC. | $34.9M | 14.6% | +0% | 13.9 |
| 4 | $CELC | Celcuity Inc. | $31.3M | 13.1% | -15% | — |
| 5 | $ZURA | Zura Bio Ltd | $16.8M | 7.0% | -4% | — |
| 6 | $WVE | Wave Life Sciences Ltd. | $11.9M | 5.0% | +0% | — |
| 7 | $PYXS | Pyxis Oncology, Inc. | $9.2M | 3.9% | +0% | — |
| 8 | $CRBU | Caribou Biosciences, Inc. | $8.3M | 3.5% | +0% | 6.1 |
| 9 | $SPRO | Spero Therapeutics, Inc. | $5.5M | 2.3% | +0% | 19.5 |
| 10 | $BHVN | Biohaven Ltd. | $4.2M | 1.8% | +0% | — |
| 11 |  $CRDF | Cardiff Oncology, Inc. | $3.7M | 1.6% | +0% | — |
| 12 |  $ZNTL | Zentalis Pharmaceuticals, Inc. | $2.0M | 0.8% | +0% | — |
| 13 |  $NXTC | NextCure, Inc. | $1.5M | 0.6% | -3% | — |
| 14 |  $AGMB | Agomab Therapeutics NV | $813,750 | 0.3% | NEW | — |
| 15 |  $QTTB | Q32 Bio Inc. | $736,731 | 0.3% | -63% | 23.1 |
| 16 |  $BOLT | Bolt Biotherapeutics, Inc. | $137,116 | 0.1% | +0% | — |
| 17 |  $DNA | Ginkgo Bioworks Holdings, Inc. | $17,363 | 0.0% | +0% | 11.7 |
| 18 |  $SENS | Senseonics Holdings, Inc. | $14,242 | 0.0% | +0% | 26.7 |
New Positions (1)
$AGMB Agomab Therapeutics NV$813,750Exited Positions (1)
$ANTX AN2 Therapeutics, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for PFIZER INC including:
Track PFIZER INC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for PFIZER INC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: PFIZER INC
13F Pro is an AI hedge fund tracker and stock research platform. For PFIZER INC (SEC CIK: 78003), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in PFIZER INC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.